The company contracted AIBMR Life Sciences to conduct the studies investigating the safety of consuming its CBG, CBN, and CBC products
Open Book Extracts (OBX), a manufacturer and distributor of cannabinoid ingredients and finished products, has completed phase one of the toxicology and safety results for its cannabinoid ingredients, cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC).
The company contracted AIBMR Life Sciences to conduct the studies investigating the safety of consuming its CBG, CBN, and CBC products. The tests will ultimately support a generally recognised as safe (GRAS) independent conclusion or New Dietary Ingredient (NDI) application. The report concluded the test articles were non-mutagenic, non-clastogenic and non-genotoxic.
Chelsea Pipkin, OBX VP of Quality Assurance, said, “Until today, there have been no comprehensive toxicological safety assessments completed on minor cannabinoids, including CBG, CBN, and CBC. The completion and publication of these safety studies on these ingredients in a peer-reviewed academic journal specialising in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”
Dave Neundorfer, OBX CEO added: “We are thrilled to advance cannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS or NDI status. As an organisation, our commitment to safety remains paramount. We look forward to setting the bar for all cannabinoid manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”